Based on future promise, I increased my investment in THLD today. I was surprised that Incyte's stock moved like it did with sparse data on mid-stage results. I believe in TH-302 and have pointed out here previously that its ideal combination partner probably remains to be determined. Nonetheless, the paradigm and this drug hold a lot of promise. I expect the stock to move back above its 200- day MA and perhaps head substantially higher soon. It is way oversold here.
Thank you, beachbum, and thanks for keeping the faith on this board. It's going on 5 months since I lost my sister to this dreaded disease, and life is not the same without her. It was her illness that brought my awareness to this company and this compound. Unfortunately, abraxane devasted her physically and emotionally. There are better treatments out there than that, and I believe that TH-302 is on its way to becoming one of them. My sister did not have the privilege of taking TH-302, because she did not qualify for the trial at the time. I am hoping that it gets approved.